Texas Oncology P.A. — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$739,266	2
2024	Research	$248,676	261
2021	Research	$47,443	46
2020	Research	$39,766	44
2019	Research	$61,184	9

Breakdown

Who paid Research payments · program years 2019–2025

Aadi Bioscience, Inc. $987,659 259 payments
EMD Serono, Inc. $78,188 88 payments
AstraZeneca Pharmaceuticals LP $41,278 6 payments
Acerta Pharma LLC $19,731 2 payments
Gilead Sciences, Inc. $9,196 3 payments
Amgen Inc. $283 4 payments

Studies the money was for Research payments · program years 2019–2025

Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract Lung or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors $634,307 189 payments
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer $353,351 70 payments
A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma $26,415 4 payments
A Phase II, Multicenter, Open Label Study of Bintrafusp alfa (M7824) Monotherapy in Participants with HMGA2-expressing Triple Negative Breast Cancer $24,026 24 payments
A Phase II single-arm trial to investigate tepotinib in advanced (Stage IIIb and IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations or MET amplification (VISION) $23,426 25 payments
A Phase 2 Open-label, Multicenter, Randomized, Multidrug Platform Study of Neoadjuvant Durvalumab Alone or in Combination with Novel Agents in Subjects with Resectable, Early-stage (I [ less than 2 cm] to IIIA) Non-small Cell Lung Cancer (NeoCOAST) $16,866 2 payments
To assess safety and tolerability describe the dose limiting toxicities determine the maximum tolerated dose MTD or the highest protocol defined dose maximum administered dose in the absence of establishing the MTD and a recommended dose for further evaluation of MEDI7247 in patients with selected hematological malignancies who have relapsed after or are refractory to prior standard therapy and for whom there is no standard salvage regimen available $13,583 1 payment
An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (bintrafusp alfa) versus Pembrolizumab as a First-line Treatment in Patients with PD-L1 Expressing Advanced Non-small Cell Lung Cancer $11,943 11 payments
An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970/M6620 in Combination With Cytotoxic Chemotherapy in Subjects With Advanced Solid Tumors $10,516 11 payments
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. $8,277 17 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.